about
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML PatientsDasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.Expression patterns of microRNAs associated with CML phases and their disease related targets.Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.Role of epigenetics in chronic myeloid leukemiaExpression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia.Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainResponse to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences.The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemiaAnalysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission
P50
Q28552307-99616B82-A3BE-4021-A3AF-BF20D05E1EE4Q33568075-20D48D21-76F2-4047-91A9-7E6413A783E1Q33577088-15422568-A30E-4515-8BB1-008994472BD8Q35009176-62FFAF40-26D8-48E7-8D77-895761F45809Q35603605-25CE51C7-8049-4379-9C66-4004D126BF66Q36939131-7D36139C-E620-42A1-BBDC-D73FDDB82667Q37588786-3AC3ECB6-D76E-467F-BD0C-710C29C127B3Q38072315-8DB057E0-3349-466B-AC32-D07CE1891EA3Q39190399-0A90D3EB-595A-473D-B0B0-3135D9291947Q39961918-93E7E06D-F8A8-418B-8640-F5A63F0AB602Q42811718-E9EE5933-1884-4323-A8B7-B4275877E0ABQ45938086-77CCB26E-CCBB-4A55-B954-1E72AF4B3435Q51090368-22A0B805-3642-4956-94EC-A35086FBBE24Q54318403-B3CB8AD2-DD2F-4608-9693-FF2D04EC162BQ84912554-31C33B55-C7A8-4D42-AE3E-20773A9B3432Q96022954-7FEDF5E8-9A87-4426-BF5F-FB745AB16455
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Kateřina Machová Poláková
@ast
Kateřina Machová Poláková
@en
Kateřina Machová Poláková
@es
Kateřina Machová Poláková
@nl
Kateřina Machová Poláková
@sl
type
label
Kateřina Machová Poláková
@ast
Kateřina Machová Poláková
@en
Kateřina Machová Poláková
@es
Kateřina Machová Poláková
@nl
Kateřina Machová Poláková
@sl
prefLabel
Kateřina Machová Poláková
@ast
Kateřina Machová Poláková
@en
Kateřina Machová Poláková
@es
Kateřina Machová Poláková
@nl
Kateřina Machová Poláková
@sl
P214
P106
P1153
26664803300
P21
P214
P31
P496
0000-0002-7398-5555
P691
P7859
viaf-183828355